Summary
Not verifiable against FDA-approved prescribing information because no Xopenex label sections were provided covering copay cards, patient assistance, or coverage/discount restrictions; therefore all evaluated claims are unsupported by the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
A "Xopenex copay card" would be a manufacturer or pharmacy-assistance coupon that helps reduce the out-of-pocket cost of Xopenex (levalbuterol).
The provided FDA label content contains no sections describing copay cards or assistance-coupon programs for Xopenex.
The exact terms of a Xopenex copay card (who is eligible, how much the discount is, and whether it works with insurance) depend on the specific program currently offered by the drug’s manufacturer or an authorized access partner.
The provided FDA label content contains no sections describing copay-card term dependencies, eligibility, discount amounts, or insurance compatibility.
Copay cards can change over time (new issuances, enrollment requirements, or program pauses).
The provided FDA label content contains no sections discussing changes/pauses to copay-card programs.
Most manufacturer copay cards are generally not usable with government insurance such as Medicare.
The provided FDA label content contains no sections addressing Medicare/government-insurance restrictions for copay cards.
Most manufacturer copay cards are often not usable with Medicaid.
The provided FDA label content contains no sections addressing Medicaid restrictions for copay cards.
Eligibility rules for copay cards vary by program.
The provided FDA label content contains no sections describing variability in copay-card eligibility rules.
It is common for copay cards to restrict use to commercially insured patients.
The provided FDA label content contains no sections describing commercial-insurance-only restrictions for copay cards.
Other cost-lowering options (if a copay card isn’t eligible) may include patient assistance programs (PAPs) based on income, pharmacy discount programs, switching to an in-formulary equivalent, and asking the prescriber about lower-cost alternatives.
The provided FDA label content contains no sections describing patient assistance programs, pharmacy discount programs, formulary switching, or prescriber discussions related to lower cost alternatives.
The discount from copay cards usually comes in one of these structures: a fixed copay limit per prescription/fill, a dollar amount off, or a capped annual benefit.
The provided FDA label content contains no sections describing typical copay-card discount structures.
Exact copay card amounts and caps depend on the current program terms.
The provided FDA label content contains no sections describing copay-card amounts/caps or dependency on current program terms.
Contradictions
Important Omissions
FDA label-based details for how any assistance, copay support, or access programs are described/qualified (e.g., whether such programs are mentioned at all in the prescribing information).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern coverage/cost assistance program characteristics rather than dosing, contraindications, or safety warnings; however, they are not supported by the supplied FDA label text, limiting label adherence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All evaluated claims are unsupported by the provided FDA label content because no relevant Xopenex prescribing information sections were supplied.
Suggested Improvement
Provide the actual FDA label sections that mention (or do not mention) copay cards/patient assistance/access programs, or remove/qualify these claims to avoid making statements that cannot be verified against the supplied label.